2ykc | pdb_00002ykc

TRICYCLIC SERIES OF HSP90 INHIBITORS

spinqualitylabelsall models 2ykc, resolution 1.67Å Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image   Print3D Structural highlights 2ykc is a 1 chain structure with sequence from Human. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance. Ligands: YKC Related: 2yi0, 2yk9, 2bsm, 1osf, 2wi3, 2ye4, 2yi5, 2ye5, 2bz5, 2yei, 2ccs, 2yeg, 1uyf, 1yc3, 1uyi, 2byi, 2ye3, 2yi6, 2vci, 2wi1, 2xjx, 2fwz, 2xdk, 1uyh, 2xjg, 2fwy, 1uyl, 1uye, 2xab, 2yeh, 2xhr, 2xht, 1uy7, 2yef, 2byh, 2wi5, 1uy9, 1yes, 2cdd, 1byq, 2yi7, 1uy8, 2wi4, 2bug, 2ye7, 2yeb, 2uwd, 2wi7, 2xhx, 2bt0, 2yej, 1yer, 2xdu, 2yec, 1uyg, 2ccu, 2xds, 2xdx, 2xk2, 2xjj, 1uyd, 2wi2, 2xdl, 1uy6, 2yee, 2ye2, 2vcj, 1yc4, 2ye9, 2c2l, 1uyk, 2cct, 2yk2, 2wi6, 1yc1, 2yea, 2ye6, 2yed, 1uyc, 1yet, 2yjx, 2jjc, 2ye8, 2yke, 2ykb Resources: FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT Function [HS90A_HUMAN] Molecular chaperone that promotes the maturation, structural maintenance and proper regulation of specific target proteins involved for instance in cell cycle control and signal transduction. Undergoes a functional cycle that is linked to its ATPase activity. This cycle probably induces conformational changes in the client proteins, thereby causing their activation. Interacts dynamically with various co-chaperones that modulate its substrate recognition, ATPase cycle and chaperone function. Publication Abstract from PubMed A novel class of heat shock protein 90 (Hsp90) inhibitors was developed after a low throughput screen (LTS) of a focused library containing approximately 21K compounds selected by virtual screening. The initial [1-{3-H-imidazo[4-5-c]pyridin-2-yl}-3,4-dihydro-2H-pyrido[2,1-a]isoindole- 6-one] (1) compound showed moderate activity (IC(50) = 7.6 muM on Hsp82, the yeast homologue of Hsp90). A high-resolution X-ray structure shows that compound 1 binds into an "induced" hydrophobic pocket, 10-15 A away from the ATP/resorcinol binding site. Iterative cycles of structure-based drug design (SBDD) and chemical synthesis led to the design and preparation of analogues with improved affinity. These optimized molecules make productive interactions within the ATP binding site as reported by other Hsp90 inhibitors. This resulted in compound 8, which is a highly potent inhibitor in biochemical and cellular assays (K(d) = 0.35 nM on Hsp90; IC(50) = 30 nM on SKBr3 mammary carcinoma cells) and in an in vivo leukemia model. Tricyclic Series of Heat Shock Protein 90 (Hsp90) Inhibitors Part I: Discovery of Tricyclic Imidazo[4,5-c]pyridines as Potent Inhibitors of the Hsp90 Molecular Chaperone.,Vallee F, Carrez C, Pilorge F, Dupuy A, Parent A, Bertin L, Thompson F, Ferrari P, Fassy F, Lamberton A, Thomas A, Arrebola R, Guerif S, Rohaut A, Certal V, Ruxer JM, Delorme C, Jouanen A, Dumas J, Grepin C, Combeau C, Goulaouic H, Dereu N, Mikol V, Mailliet P, Minoux H J Med Chem. 2011 Oct 27;54(20):7206-19. Epub 2011 Oct 5. PMID:21972823 From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See Also Heat Shock Proteins

Proteopedia Page Contributors and Editors (what is this?)

OCA